Generate Biomedicines Discloses ERS Poster Embargo Breach on GB-0895

What Happened
Generate Biomedicines, Inc. announced on August 25, 2026 (via an 8-K, Item 7.01) that draft copies of three posters accepted for presentation at the European Respiratory Society Congress 2026 (Sept 5–9, 2026) were accidentally made public on the ERS website before the embargo the company believed ran until 6:01 p.m. ET on September 7, 2026. The posters report results from ongoing clinical trials sponsored by the company for its long‑acting anti‑TSLP antibody GB-0895. As a precaution under Regulation FD, the company furnished the final poster files as Exhibit 99.1 with the filing.

Key Details

• Date of disclosure filing: August 25, 2026 (signed by Jason Silvers, President & CFO).
• Event: Draft posters accepted for ERS 2026 were posted early on the ERS site; embargo was expected to expire Sept 7, 2026 at 6:01 p.m. ET.
• Content: Three posters on GB-0895 covering durable pharmacologic activity supporting 6‑month dosing in asthma, two Phase 3 randomized double‑blind placebo‑controlled SOLAIRIA studies (SOLAIRIA‑1 & SOLAIRIA‑2) in severe uncontrolled asthma, and pharmacology in adults with COPD.
• Company action: Furnished the final poster versions as Exhibit 99.1 to the SEC 8‑K.

Why It Matters
This filing is a Regulation FD disclosure notifying investors that clinical data for GB-0895 were made public earlier than intended and that final posters have been provided to the SEC. Retail investors should be aware the documents include clinical trial results (including Phase 3 study descriptions) for GB-0895; interested investors can review Exhibit 99.1 in the 8‑K for the specific data released.